CDER Director Singles Out Aurinia’s Drug in Questioning Reliance on Surrogate Endpoints

Without naming Aurinia Pharmaceuticals, George Tidmarsh in a now-deleted LinkedIn post claimed that lupus nephritis companies have not conducted post-approval studies “to demonstrate a benefit on hard clinical endpoints.”